Abstract
Stroke strikes often suddenly, causes long-term disability and death, and is a huge economical burden for the society, not to mention the human tragedy for the patient and the family. At least 15% of stroke survivors will have a second stroke during the next five years, quarter of which prove out to be fatal within four weeks [1]. Secondary prevention of ischemic stroke (IS) targets at reducing stroke recurrence by means of 1) detection and modification of risk factors, 2) antithrombotic or anticoagulant treatment, and 3) surgical interventions for selected patient subgroups. In this review we will discuss these issues in detail and also offer our personal suggestions for treatment choices. Detecting and treating the modifiable risk factors is the major challenge of secondary prevention of IS.
Keywords: stroke, prevention, cerebrovascular disease, risk factors, antithrombotic agents, brain infarct, endarterectomy
Current Drug Targets
Title: Secondary Prevention of Ischemic Stroke
Volume: 5 Issue: 5
Author(s): Kirsi Rantanen and Turgut Tatlisumak
Affiliation:
Keywords: stroke, prevention, cerebrovascular disease, risk factors, antithrombotic agents, brain infarct, endarterectomy
Abstract: Stroke strikes often suddenly, causes long-term disability and death, and is a huge economical burden for the society, not to mention the human tragedy for the patient and the family. At least 15% of stroke survivors will have a second stroke during the next five years, quarter of which prove out to be fatal within four weeks [1]. Secondary prevention of ischemic stroke (IS) targets at reducing stroke recurrence by means of 1) detection and modification of risk factors, 2) antithrombotic or anticoagulant treatment, and 3) surgical interventions for selected patient subgroups. In this review we will discuss these issues in detail and also offer our personal suggestions for treatment choices. Detecting and treating the modifiable risk factors is the major challenge of secondary prevention of IS.
Export Options
About this article
Cite this article as:
Rantanen Kirsi and Tatlisumak Turgut, Secondary Prevention of Ischemic Stroke, Current Drug Targets 2004; 5 (5) . https://dx.doi.org/10.2174/1389450043345425
DOI https://dx.doi.org/10.2174/1389450043345425 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Acetylation Control of Cancer Cell Metabolism
Current Pharmaceutical Design HGF as Angiogenic Factor and Therapeutic Approach
Current Signal Transduction Therapy Cardiovascular Side Effects of New Antidepressants and Antipsychotics: New Drugs, old Concerns?
Current Pharmaceutical Design Therapeutic Angiogenesis in Ischemic Tissues by Growth Factors and Bone Marrow Mononuclear Cells Administration: Biological Foundation and Clinical Prospects
Current Stem Cell Research & Therapy A beta oligomerization A Therapeutic Target for Alzheimers Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Current Therapeutic Concepts in Peripartum Cardiomyopathy
Current Pharmaceutical Design Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design The Role of Adipokines in Hypertension and Cardiovascular Disease
Current Hypertension Reviews Energy Metabolism in the Normal and in the Diabetic Heart
Current Pharmaceutical Design Biological Therapies: Effects of Proinflammatory Pathways and their Inhibition on the Myocardium of Rheumatoid Athritis Patients
Current Medicinal Chemistry Beneficial Extracardiac Effects of Cardiovascular Medications
Current Cardiology Reviews Oxidative and Inflammatory Events in Prion Diseases: Can They Be Therapeutic Targets?
Current Aging Science Drug Repositioning: A Smart Approach for Combating SARS-CoV-2
Anti-Infective Agents The Potential of Secondary Metabolites from Plants as Drugs or Leads Against Protozoan Neglected Diseases – Part I
Current Medicinal Chemistry Molecule of the Month
Current Topics in Medicinal Chemistry Cathinone Neurotoxicity (“The “3Ms”)
Current Neuropharmacology ACE Inhibition Prevents Diastolic Ca2+ Overload and Loss of Myofilament Ca2+ Sensitivity after Myocardial Infarction
Current Molecular Medicine Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine AMP-Activated Protein Kinase (AMPK): Regulation of Metabolic Gene Expression
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents